A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms HOVON 141 CLL/ VIsion
- 20 Jul 2017 Planned End Date changed from 1 May 2027 to 1 Jul 2027.
- 20 Jul 2017 Planned primary completion date changed to 1 Jul 2027.
- 10 Jun 2017 Status changed from not yet recruiting to recruiting.